U.S. Intravenous Solutions Market Size, Share & Trends Analysis Report By Type (TPN, PPN), By Nutrients (Carbohydrates, Vitamins & Minerals, Single-dose Amino Acids), And Segment Forecasts, 2024 - 2030

U.S. Intravenous Solutions Market Trends

The U.S. intravenous solutions market size was estimated at USD 4.67 billion in 2023 and is projected to grow at a CAGR of 7.8% from 2024 to 2030. The market growth is observed due to the rising prevalence of diseases and an increasing number of surgeries. In addition, the rising number of geriatric population susceptible to non-communicable diseases such as cancer, neurological disorders, cardiovascular disorders, and spinal injuries is likely to impact the market growth. The U.S. held over 35% share in the global intravenous solutions market.

For instance, according to the 2020 census data, one in six people in the U.S. is aged 65 and above, contributing to 16.8% of the total population of the U.S. in 2020. The persistent COVID-19 infection amongst the U.S. population accounts for hospitalization for disease cure. Older adults are easily susceptible to infectious diseases and need hospital treatment by administering parenteral nutrition (PN), which helps maintain strength, energy, and hydration. According to the data published by the Centers for Disease Control and Prevention (CDC), older adults accounted for 62.9% of all COVID-19-associated hospitalizations.

The rising number of cancer cases in the country is expected to drive the market growth. According to an article published by the American Cancer Society, cancer cases in the US are likely to cross a mark of 2 million in the coming years. Breast, lung, bronchus, prostate, and colorectal cancers are the most common cancers in the U.S. The compromised immunity in cancer disease boosts the need for parenteral nutrition products containing glutamine, phospholipids, glucose, and amino acids.

Market Concentration & Characteristics

The industry growth stage is medium, and the pace is accelerating. The innovations and new developments in the nutritional solution formulations and delivery systems contribute to the industry’s growth. The availability of advanced healthcare facilities and the wide presence of hospitals and ambulatory surgical centers across the country facilitate industry growth. Moreover, an increase in the number of intravenous (IV) solutions infusion centers and med spas providing products and services to patients with chronic diseases, along with the treatment for mental health disorders, has been observed over the past years.

Key companies engage in strategic collaborations and acquisitions to expand their market presence and enhance competitiveness. For instance, in May 2022, Fresenius Kabi AG completed acquisition of Ivenix, Inc., resulting in Fresenius’ product range expansion.

Intravenous solutions are regulated as pharmaceutical products, subject to stringent quality standards. For the production quality compliance of intravenous solutions, companies are likely to adhere to Good Manufacturing Practices (GMP) and other regulatory guidelines to ensure product safety and quality.

A high level of end-user concentration is observed due to the rising prevalence of chronic diseases. Hospitals and clinics are the major consumers of intravenous solutions, utilizing them for a wide range of medical procedures, treatments, and patient care. For instance, according to the 2022 data published by the American Hospital Association, 6,120 hospitals in the U.S. Ambulatory surgery centers also represent a notable share of end users in the market. These centers rely on intravenous solutions for various surgical procedures and post-operative care, driving demand within this sector. The feasibility of setting up home care facilities has made it easier for patients to use drips in the comfort of their homes rather than at hospitals.

Type Insights

Based on type, the intravenous solutions segment is categorized into total parenteral nutrition (TPN) and peripheral parenteral nutrition (PPN). The TPN segment led the market with the largest revenue share of 67.02% in 2023 and is expected to grow at the fastest CAGR of 8.0% over the forecast period. Total parenteral nutrition is a method of administering a complete range of nutrients directly into the bloodstream through an intravenous (IV) technique. TPN solutions are more concentrated than peripheral parenteral nutrition solutions and are commonly used in surgical intensive care units (ICUs). According to the Society of Critical Care Medicine, more than 5 million patients are admitted to ICUs annually in the U.S.

Based on a study by MDPI, early administration of peripheral parenteral nutrition (PPN) can provide several benefits to patients undergoing colorectal surgery. When PPN supplementation is combined with adherence to Enhanced Recovery after Surgery (ERAS) programs, it can significantly reduce postoperative complications. Patients who received PPN had a lower risk of complications than those who received conventional fluid therapy. Furthermore, PPN can decrease the likelihood of complications worsening or developing into major issues.

Nutrients Insights

Based on nutrient, the single dose amino acid solution segment led the market with the largest revenue share of 31.30% in 2023. Different studies suggest that single-dose amino acids provide a complete protein source, and can be easily customized with other parenteral formulations for administration.

The vitamins and minerals segment is expected to grow at the fastest CAGR over the forecast period. Vitamins play a crucial role in the formation of red blood cells, blood clotting, and maintaining mucus membranes. Their deficiency can lead to various conditions such as anaemia, beriberi, pellagra, and chronic mental disorders. Treatment for such deficiencies involves either parenteral or enteral nutrition.

Minerals are organic chemicals that are essential for regulating metabolic pathways, such as β-carotene, sodium chloride, magnesium, potassium, and phosphorous. Lack of minerals can lead to weak bones, a weakened immune system, and fatigue due to poor mineral absorption. Parental nutrition (PN) therapies can be used for such deficiencies.

Key U.S. Intravenous Solutions Company Insights

Some of the key players operating in the market include Fresenius Kabi AG, Pfizer Inc., Baxter , JW Life Science, ICU Medical, Inc., Grifols USA, LLC, B. Braun Medical Inc, Amphastar Pharmaceuticals, Inc., Athenex, Inc., Rockwell Medical, Inc., Exela Pharma Sciences, LLC, among others

• Baxter International holds a diversified product portfolio in renal care, nutrition, respiratory care, hospital beds, and connected care, with a strong presence in intravenous solutions and therapies

• Fresenius Kabi AG is an infusion therapy and clinical products company offering medicines for various diseases, including oncology, anaesthesia, analgesia, anti-infectives, parenteral nutrition, IV solutions, and many critical care therapies

Recent Developments

• In February 2024, B. Braun Medical Inc. launched its new Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection, expanding its heparin products portfolio

• In March 2022, Fresenius Kabi received US FDA approval for SMOFlipid lipid injectable emulsion for pediatric patients in the US

U.S. Intravenous Solutions Market Report Scope

U.S. Intravenous Solutions Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. intravenous solutions market report based on type, and nutrients:

• Type Outlook (Volume, Thousand Units; Revenue, USD Billion, 2018 - 2030)

  • Total Parenteral Nutrition (TPN)

  • Peripheral Parenteral Nutrition (PPN)

• Nutrients Outlook (Volume, Thousand Units; Revenue, USD Billion, 2018 - 2030)

  • Carbohydrates

  • Vitamins & Minerals

  • Single-dose Amino Acids

  • Parenteral Lipid Emulsion

  • Others